Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
about
Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast CancerThe role of preoperative systemic treatment in patients with breast cancerChinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta-AnalysisNeoadjuvant nab-paclitaxel in the treatment of breast cancerNeoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the LiteraturePostmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available dataHow to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancerCurrent approaches in treatment of triple-negative breast cancerAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineNeoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implicationsRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerRecommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Neoadjuvant therapy in the treatment of breast cancerExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Reduced Let-7a Is Associated with Chemoresistance in Primary Breast CancerDiffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data.National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer.S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Breast cancer local recurrence under the form of inflammatory carcinoma, treated with concurrent radiation and chemotherapy, a case reportTargeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancerAccuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients.Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy.Triple-negative breast cancer: role of specific chemotherapy agentsPretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).Utility of FDG-PET/CT in the evaluation of the response of locally advanced breast cancer to neoadjuvant chemotherapyIn vivo 1H MRS in the assessment of the therapeutic response of breast cancer patientsLocoregional recurrence after neoadjuvant chemotherapy.Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data
P2860
Q26740393-DC2CC852-710E-4FFC-AD13-BEA2E3AE3455Q26746034-B35C7D9F-F825-4DB3-9138-166E3DBA7671Q26748777-D6126C28-374F-440D-AD75-43BD26748CC2Q26748822-1289780A-5F7B-41AF-8EC6-023537F9CF59Q26751249-2B1E3A93-99C5-4875-BECE-F6239B407396Q26769835-A1102F6D-35C5-4338-AEC0-9C1882522A3BQ26798419-13BA270B-3FCF-400C-B8DF-13D198581619Q26801549-E5071EBD-E5EF-48E8-902A-FEA76BD85EDBQ26853619-8AB8C845-72CB-4064-A106-3C1E629C59D7Q27001729-9E2219CD-2C1C-4527-87B1-04DDB7029DB4Q27028084-6983837B-94A1-45B7-8966-8502259DFC0EQ27304609-AFC80A36-6AFE-4415-A7F6-1CF63EAB584AQ27694514-886FB67C-36FD-4590-97F2-1FF65E694548Q28066481-461E32C6-501A-4FF9-A73D-4EDDA454DD55Q28291395-4271FBE5-BD5B-4928-B4CA-FC3A3F338FF4Q28546834-307DC79B-D123-4B59-8492-DF7C96DBDF08Q28710339-4B268F2E-A5E8-4AA5-A80E-A64E0976994DQ30240816-9701B660-10DC-4406-8A6E-22A7FA4A1C57Q30244077-A13EFCCA-CD01-4648-9E43-1536A08C7192Q30588206-EE993C1E-3051-48B7-9775-E5ED222F1D3CQ30837599-715D0AF6-D80A-47DC-916E-C6BC692815B0Q31150366-F716080C-16CB-41C6-B11C-C6899C8CCE25Q33388534-A8FB0AE8-1EAF-4C7B-A67F-3ECB7CFEA7A2Q33430463-E5824017-A976-4EF6-A24D-F74F2C1E6028Q33599465-1CE2800D-9D27-489B-8C51-AE034DFD8613Q33643492-2245FD8D-DD9D-4CE2-AF86-83FAB8844022Q33698446-57F24836-AA86-43CF-9FA3-1EF950BD516DQ33751728-E2854417-5CF0-4814-84D5-7607141C32C1Q33798788-27321E7E-D884-41B7-8335-F7512F563E3CQ33829617-A50EDFDD-BD76-448E-A403-8B79C044B734Q33844469-53F826B9-588A-4D89-9610-44B3BCB3A5BDQ33862578-C3777026-5ED3-4C9D-8508-288D8223A9A8Q33886353-DCE13184-3326-468F-ABD3-40AE98E97065Q33889349-165B2CA9-1C7F-4AC0-BFA2-711EB94CE58DQ33900930-416E7B6E-A855-45E0-961E-1F33B8CD6729Q33913615-46D6C04F-0CB0-4466-8E55-4C9592E6749AQ33966252-40A7C871-C2AD-440A-9E16-49C9B87B592EQ33972737-EF5BB577-3E82-41E6-A86B-B4980D377AA3Q33972948-CF307C68-5DBC-4D52-9C4E-4168666E1538Q33994633-4C285927-5706-42EE-92AC-4658CFEBF6EE
P2860
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Preoperative chemotherapy: upd ...... oject Protocols B-18 and B-27.
@en
Preoperative chemotherapy: upd ...... oject Protocols B-18 and B-27.
@nl
type
label
Preoperative chemotherapy: upd ...... oject Protocols B-18 and B-27.
@en
Preoperative chemotherapy: upd ...... oject Protocols B-18 and B-27.
@nl
prefLabel
Preoperative chemotherapy: upd ...... oject Protocols B-18 and B-27.
@en
Preoperative chemotherapy: upd ...... oject Protocols B-18 and B-27.
@nl
P2093
P356
P1476
Preoperative chemotherapy: upd ...... oject Protocols B-18 and B-27.
@en
P2093
André Robidoux
Charles E Geyer
Deimante Tamkus
Eduardo R Pajon
Eleftherios P Mamounas
Harry D Bear
James L Hoehn
Jean Robert
Karen M King
Mary Johanna Wright
P304
P356
10.1200/JCO.2007.15.0235
P407
P577
2008-02-01T00:00:00Z